Roughly half a year after Biogen’s $7.3 billion buyout of rare disease specialist Reata Pharmaceuticals, the companies’ blockbuster bid for Reata’s Friedreich’s ataxia (FA) drug Skyclarys is starting to take shape.
Registered office
11 Lyons Walk
Shaftesbury
Dorset
SP7 8JF
office@icr-global.org